Mylan-Atovaquone/Proguanil 250 mg

MYLAN-Atovaquone/Proguanil 250 MG tablets are a combination medication used to prevent and treat malaria. This oral treatment is manufactured by Mylan Pharmaceuticals ULC in Canada.

MYLAN-Atovaquone/Proguanil 250 MG tablets are primarily used for the prevention and treatment of malaria, a mosquito-borne disease caused by parasites. This medication is often prescribed for travelers to areas where malaria is common, as well as for those who have been exposed to the disease. The combination of atovaquone and proguanil works together to interfere with the growth of parasites in the red blood cells.

Common effects of MYLAN-Atovaquone/Proguanil 250 MG tablets may include stomach pain, nausea, vomiting, diarrhea, headache, and dizziness. Some users might also experience loss of appetite, mouth sores, or unusual dreams. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

MYLAN-Atovaquone/Proguanil 250 MG tablets should be handled with care. Store the medication in a cool, dry place away from direct sunlight and out of reach of children. It is important to follow the prescribed dosage and duration of treatment. Do not take this medication if you are allergic to atovaquone or proguanil. Inform your healthcare provider about any other medications you are taking to avoid potential interactions.

MYLAN-Atovaquone/Proguanil 250 MG tablets may interact with certain medications, including those used to treat seizures, HIV/AIDS, and other infections. Alcohol and other substances that affect the liver may also interact with this medication. It is important to discuss all current medications and supplements with your healthcare provider before starting this treatment.